期刊文献+

23价肺炎球菌多糖疫苗稳定性考察 被引量:8

Stability of 23-valent pneumococcal polysaccharide vaccine
原文传递
导出
摘要 目的:考察23价肺炎球菌多糖疫苗在2~8℃条件存放24,27个月的稳定性,以及在(37±2)℃和(25±2)℃条件下存放的加速稳定性。方法:选取2008年生产的3批23价肺炎球菌多糖疫苗在2~8℃存放24,27个月后进行外观检查、鉴别试验、多糖含量、pH值、苯酚含量、氯化钠含量、无菌检查、热原检查、异常毒性检查;选取2011年生产的3批23价肺炎球菌多糖疫苗在(37±2)℃条件分别存放1,2,3,4周和在(25±2)℃条件分别存放1,2,3个月后进行鉴别试验和多糖含量测定、外观检查、pH值和苯酚含量测定。结果:疫苗2~8℃存放24,27个月,检定结果均符合质量标准的要求;疫苗(37±2)℃和(25±2)℃存放分别从第3周和第2个月开始,个别型别的多糖含量低于质量标准要求,其余各项检测指标均符合质量标准的要求。结论:23价肺炎球菌多糖疫苗在2~8℃条件存放至24个月的有效期质量是稳定的;在(37±2)℃和(25±2)℃条件存放的加速稳定性表明合格的疫苗分别最多能存放2周和1个月。 Objective :To investigate the stability of 23-vaient pneumococcal polysaccharide vaccine stored at 2 - 8 ℃ for 24, 27 months, respectively, and accelerated stability of the vaccine stored at (37 ±2) ℃ and (25 ± 2) ℃. Methods: 3 batches of vaccine produced in 2008 were selected and stored at 2 - 8 ℃ for 24, 27 months, then carrying out tests including appearance inspection, identity test, polysaccharide content, pH, phenol content, sodium chloride content, sterility test, pyrogen test, test for abnormal toxicity. 3 batches of vaccine produced in 2011 were stored at (37±2) ℃ for 1 , 2, 3, 4 weeks, respectively, and at (25 ±2) ℃ for 1, 2, 3 months respectively, then carrying out tests including appearance inspection, identity test, polysaccharide content, pH, phenol content. Results: Test results of the vaccine stored at 2 - 8 ℃ for 24 and 27 months were in line with the requirements of quality standards. The vaccine stored at (37 ±2) ℃ for 3 weeks and (25 ± 2) ℃ for 2 months, the polysaceharide content results showed the individual type of polysaccharide content was substandard, the rest test met the quality standards. Conclusion: The quality of 23-valent pneumococcal polysaccharide vaccine stored at 2 - 8 ℃ for 24 months was stable. The qualified vaccine could be stored for 2 weeks and 1 month at (37±2) ℃ and (25±2) ℃ at most, respectively.
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第10期1115-1118,共4页 Chinese Journal of New Drugs
基金 国家科技支撑计划(2008BAI66B06)
关键词 23价肺炎球菌多糖疫苗 有效期 稳定性 23-valent pneumococcal polysaccharide vaccine period of validity stability
  • 相关文献

参考文献9

  • 1杨耀,栗克喜,宋绍忠,张云,江山,谢全海,兰芳,黄剑,黎云东,李凤祥,袁曾麟,郭淑英,石继春,何莉.23价肺炎球菌多糖疫苗临床试验[J].预防医学情报杂志,2007,23(4):390-391. 被引量:34
  • 2BUTLER JC, BREIMAN RF, CAMPBELL JF, et al. Pneumo- coccal polysaccharide vaccine efficacy[ J]. JAMA, 1993, 270 (15) :1826 - 1831.
  • 3SHAPIRO ED, BERG AT, AUSTRIAN R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine [ J ]. N Engl J Med, 1991, 325(21 ) :1453 - 1460.
  • 4杨耀,栗克喜,宋绍忠,张云,江山,黄镇,谢全海,兰芳,黄健,毕俊红,邓雪莲,李凤祥,袁曾麟,郭淑英,石继春,何莉.23价肺炎链球菌荚膜多糖疫苗的研制[J].中国生物制品学杂志,2000,13(3):154-156. 被引量:15
  • 5国家食品药品监督管理局.23价肺炎球菌多糖疫苗制造及枪定试行规程YBS00092005[S].2005:1-9.
  • 6国家食品药品监督管理局.23价肺炎球菌多糖疫苗药晶标准WS4-(S-004),2010Z[S].2010:1-12.
  • 7LEXAU CA, LYNFIELD R, DANILA R, et al. Changing epide- miology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine[ J ]. JAMA, 2005, 294(16) :2043 -2051.
  • 8SMITH KJ, ZIMMERMAN RK, LIN C J, et al. Alternative strat- egies for adult pneumococcal polysaccharide vaccination: a cost- effectiveness analysis [ J ]. Vaccine, 2008, 26 ( 11 ) : 1420 - 1431.
  • 9国家食品药品监督管理局药品认证中心.药品GMP指南.质量管理体系[M].北京:中国医药科技出版社,2011:164-171.

二级参考文献8

  • 1[1]Recommendation of the public health service advisory committee on immunization practices pneumococcal polysaccharide vaccine. Morbidity and Mortality Weekly Report,1978,27(4):25.
  • 2[2]Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med,1964,60:759-776.
  • 3[3]Wenger J D, Hightower A W, Facklam R R, et al. Bacterial meningitis in the united states,1986:Report of a multistate surveillance study. J Infect Dis,1990,162:1316-1323.
  • 4[4]Fedson DS .Pneumococcal vaccine. In:Plotkin SA.Morhmer EA. Vaccines Philadelphia,Pa:WB Saunders Co,1988,271-299.
  • 5[5]Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation Pneumococcal capsular polysaccharide vaccine with emphasis oa the cross-reactive types withen groups. J Infect Dis,1983,148:1136-1159.
  • 6Butler J C,Breiman R F,Campbell J F,et al.Pneumococcal polysaccharide vaccine efficacy[J].JAMA,1993,270:1826-1831.
  • 7Chu C,Schneerson R,Robbins J B,et al.Further studies on the immunogenicity of H.influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates[J].Infect Immun,1983,39:233.
  • 8袁曾麟.肺炎球菌感染及其疫苗预防[J].中国计划免疫,1997,3(2):90-93. 被引量:11

共引文献43

同被引文献45

引证文献8

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部